Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.
Sareum's most advanced development programme (Chk1) was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is currently completing the second of two Phase 2 clinical trials, being conducted by licence partner Sierra Oncology, with a further two trials planned. The other development programmes (TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer, Aurora+FLT3) are in preclinical development.
We are also looking for grant and other funding opportunities to investigate the potential of our TYK2/JAK1 inhibitors to treat the "cytokine storm" immune system over-reaction that is often fatal to patients suffering from Covid-19 and other viral lung diseases.